Abstract
Many complex psychiatric disorders are characterised by a spectrum of social difficulties. These symptoms lie on a behavioural dimension that is shared with social behaviour in the general population, with substantial contributions of genetic factors. However, shared genetic links may vary across psychiatric disorders and social symptoms. Here, we systematically investigate heterogeneity in shared genetic liabilities with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorders (ASD), bipolar disorder (BP), major depression (MD) and schizophrenia, across a spectrum of different social symptoms. Specifically, longitudinally assessed low-prosociality and peer-problem scores in two UK population-based/community-based cohorts (ALSPAC, N ≤ 6174, 4-17 years; TEDS, N ≤ 7112, 4-16 years; parent- and teacher-reports) were regressed on polygenic risk scores for ADHD, ASD, BP, MD, and schizophrenia, as informed by genome-wide summary statistics from large consortia, using negative binomial regression models. Across ALSPAC and TEDS, we replicated univariate polygenic associations between social behaviour and risk for ADHD, MD, and schizophrenia. Modelling univariate genetic effects across both cohorts with random-effect meta-regression revealed evidence for polygenic links between social behaviour and ADHD, ASD, MD, and schizophrenia risk, but not BP, where differences in age, reporter and social trait captured 45-88% in univariate effect variation. For ADHD, MD, and ASD polygenic risk, we identified stronger association with peer problems than low prosociality, while schizophrenia polygenic risk was solely associated with low prosociality. The identified association profiles suggest marked differences in the social genetic architecture underlying different psychiatric disorders when investigating population-based social symptoms across 13 years of child and adolescent development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and FS and BSTP will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. FS, EV, MvD, BSTP and SEF are supported by the Max Planck Society. BSTP is supported by the Simons Foundation (Award ID: 514787). The authors gratefully acknowledge the ongoing contribution of the participants in the TEDS and their families. TEDS is supported by a programme grant to RP from the UK Medical Research Council (MR/M021475/1 and previously G0901245), with additional support from the US National Institutes of Health (AG046938). RP is supported by a Medical Research Council Professorship award (G19/2). The research leading to these results has also received funding from the European Research Council under the European Unions Seventh Framework Programme (FP7/2007-2013)/ grant agreement number 602768. This project has received funding from the European Unions Horizon 2020 research and innovation programme, Marie Sklodowska Curie Actions (MSCA-ITN-2016) Innovative Training Networks (CAPICE grant 721567). KR is supported by a Sir Henry Wellcome Postdoctoral Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ALSPAC Ethics and Law Committee the Local Research Ethics Committees The Human Tissue Act (2004) Kings College Londons ethics committee for the Institute of Psychiatry Psychology and Neuroscience (05.Q0706/228)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
e-mail Andrea Allegrini: andrea.allegrini{at}kcl.ac.uk; e-mail Jan Buitelaar: jan.buitelaar{at}radboudumc.nl; e-mail Ellen Verhoef: ellen.verhoef{at}mpi.nl; email Marjolein van Donkelaar: marjolein.vandonkelaar{at}mpi.nl; e-mail Robert Plomin: robert.plomin{at}kcl.ac.uk; e-mail Kaili Rimfeld: kaili.rimfeld{at}kcl.ac.uk; e-mail Simon Fisher: simon.fisher{at}mpi.nl
Data Availability
Data is available via the Avon Longitudinal Study for Parents and Children (ALSPAC;http://www.bristol.ac.uk/alspac/researchers/access/)and via the Twins Early Development Study (TEDS;https://www.teds.ac.uk/researchers/teds-data-access-policy). Publicly available psychiatrich summary statistics are avialable via http://www.med.unc.edu/pgc.
